Correction to: Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis (Leukemia, (2021), 35, 2, (440-453), 10.1038/s41375-020-01111-2)

Hagop M. Kantarjian; Timothy P. Hughes; Richard A. Larson; Dong Wook Kim; Surapol Issaragrisil; Philipp le Coutre; Gabriel Etienne; Carla Boquimpani; Ricardo Pasquini; Richard E. Clark; Viviane Dubruille; Ian W. Flinn; Slawomira Kyrcz-Krzemien; Ewa Medras; Maria Zanichelli; Israel Bendit; Silvia Cacciatore; Ksenia Titorenko; Paola Aimone; Giuseppe Saglio; Andreas Hochhaus

doi:10.1038/s41375-021-01306-1

Correction to: Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis (Leukemia, (2021), 35, 2, (440-453), 10.1038/s41375-020-01111-2)

Hagop M. Kantarjian, Timothy P. Hughes, Richard A. Larson, Dong Wook Kim, Surapol Issaragrisil, Philipp le Coutre, Gabriel Etienne, Carla Boquimpani, Ricardo Pasquini, Richard E. Clark, Viviane Dubruille, Ian W. Flinn, Slawomira Kyrcz-Krzemien, Ewa Medras, Maria Zanichelli, Israel Bendit, Silvia Cacciatore, Ksenia Titorenko, Paola Aimone, Giuseppe SaglioAndreas Hochhaus

Leukemia

Research output: Contribution to journal › Comment/debate › peer-review

5 Scopus citations

Abstract

We found an error within Fig. 2B of the manuscript, and unfortunately this was not caught prior to submission and publication. Attached please find the corrected Fig. 2B.

Original language	English (US)
Pages (from-to)	2142-2143
Number of pages	2
Journal	Leukemia
Volume	35
Issue number	7
DOIs	https://doi.org/10.1038/s41375-021-01306-1
State	Published - Jul 2021

ASJC Scopus subject areas

Hematology
Oncology
Cancer Research

Access to Document

10.1038/s41375-021-01306-1

Fingerprint

Dive into the research topics of 'Correction to: Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis (Leukemia, (2021), 35, 2, (440-453), 10.1038/s41375-020-01111-2)'. Together they form a unique fingerprint.

Cite this

Kantarjian, H. M., Hughes, T. P., Larson, R. A., Kim, D. W., Issaragrisil, S., le Coutre, P., Etienne, G., Boquimpani, C., Pasquini, R., Clark, R. E., Dubruille, V., Flinn, I. W., Kyrcz-Krzemien, S., Medras, E., Zanichelli, M., Bendit, I., Cacciatore, S., Titorenko, K., Aimone, P., ... Hochhaus, A. (2021). Correction to: Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis (Leukemia, (2021), 35, 2, (440-453), 10.1038/s41375-020-01111-2). Leukemia, 35(7), 2142-2143. https://doi.org/10.1038/s41375-021-01306-1

Correction to: Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis (Leukemia, (2021), 35, 2, (440-453), 10.1038/s41375-020-01111-2). / Kantarjian, Hagop M.; Hughes, Timothy P.; Larson, Richard A. et al.
In: Leukemia, Vol. 35, No. 7, 07.2021, p. 2142-2143.

Research output: Contribution to journal › Comment/debate › peer-review

Kantarjian, HM, Hughes, TP, Larson, RA, Kim, DW, Issaragrisil, S, le Coutre, P, Etienne, G, Boquimpani, C, Pasquini, R, Clark, RE, Dubruille, V, Flinn, IW, Kyrcz-Krzemien, S, Medras, E, Zanichelli, M, Bendit, I, Cacciatore, S, Titorenko, K, Aimone, P, Saglio, G & Hochhaus, A 2021, 'Correction to: Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis (Leukemia, (2021), 35, 2, (440-453), 10.1038/s41375-020-01111-2)', Leukemia, vol. 35, no. 7, pp. 2142-2143. https://doi.org/10.1038/s41375-021-01306-1

Kantarjian HM, Hughes TP, Larson RA, Kim DW, Issaragrisil S, le Coutre P et al. Correction to: Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis (Leukemia, (2021), 35, 2, (440-453), 10.1038/s41375-020-01111-2). Leukemia. 2021 Jul;35(7):2142-2143. doi: 10.1038/s41375-021-01306-1

@article{6b3d2e50a3bf4409b2c57d124958d8bb,

title = "Correction to: Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis (Leukemia, (2021), 35, 2, (440-453), 10.1038/s41375-020-01111-2)",

abstract = "We found an error within Fig. 2B of the manuscript, and unfortunately this was not caught prior to submission and publication. Attached please find the corrected Fig. 2B.",

author = "Kantarjian, {Hagop M.} and Hughes, {Timothy P.} and Larson, {Richard A.} and Kim, {Dong Wook} and Surapol Issaragrisil and {le Coutre}, Philipp and Gabriel Etienne and Carla Boquimpani and Ricardo Pasquini and Clark, {Richard E.} and Viviane Dubruille and Flinn, {Ian W.} and Slawomira Kyrcz-Krzemien and Ewa Medras and Maria Zanichelli and Israel Bendit and Silvia Cacciatore and Ksenia Titorenko and Paola Aimone and Giuseppe Saglio and Andreas Hochhaus",

note = "Publisher Copyright: Copyright {\textcopyright} The Author(s), under exclusive licence to Springer Nature Limited 2021.",

year = "2021",

month = jul,

doi = "10.1038/s41375-021-01306-1",

language = "English (US)",

volume = "35",

pages = "2142--2143",

journal = "Leukemia",

issn = "0887-6924",

publisher = "Nature Publishing Group",

number = "7",

}

TY - JOUR

T1 - Correction to

T2 - Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis (Leukemia, (2021), 35, 2, (440-453), 10.1038/s41375-020-01111-2)

AU - Kantarjian, Hagop M.

AU - Hughes, Timothy P.

AU - Larson, Richard A.

AU - Kim, Dong Wook

AU - Issaragrisil, Surapol

AU - le Coutre, Philipp

AU - Etienne, Gabriel

AU - Boquimpani, Carla

AU - Pasquini, Ricardo

AU - Clark, Richard E.

AU - Dubruille, Viviane

AU - Flinn, Ian W.

AU - Kyrcz-Krzemien, Slawomira

AU - Medras, Ewa

AU - Zanichelli, Maria

AU - Bendit, Israel

AU - Cacciatore, Silvia

AU - Titorenko, Ksenia

AU - Aimone, Paola

AU - Saglio, Giuseppe

AU - Hochhaus, Andreas

PY - 2021/7

Y1 - 2021/7

N2 - We found an error within Fig. 2B of the manuscript, and unfortunately this was not caught prior to submission and publication. Attached please find the corrected Fig. 2B.

AB - We found an error within Fig. 2B of the manuscript, and unfortunately this was not caught prior to submission and publication. Attached please find the corrected Fig. 2B.

UR - http://www.scopus.com/inward/record.url?scp=85107532351&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85107532351&partnerID=8YFLogxK

U2 - 10.1038/s41375-021-01306-1

DO - 10.1038/s41375-021-01306-1

M3 - Comment/debate

C2 - 34108614

AN - SCOPUS:85107532351

SN - 0887-6924

VL - 35

SP - 2142

EP - 2143

JO - Leukemia

JF - Leukemia

IS - 7

ER -

Correction to: Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis (Leukemia, (2021), 35, 2, (440-453), 10.1038/s41375-020-01111-2)

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this